- Over ons
- Onze geneesmiddelen
- Onderzoek & ontwikkeling
- Jobs bij Teva
“Adverse event” means an unwanted, unintended or harmful event in relation to the use of a Teva medicinal product.
“Personal data” means information that relates to any living identifiable individual (e.g. you, your medical practitioner or your family member).
Teva and your privacy
If you are a patient we may also be provided with information about you by a third party reporting an adverse event that affected you. Such third parties may include medical professionals, lawyers, relatives or other members of the public.
Information we collect and why we collect it
For pharmacovigilance purposes Teva is under legal obligations to collect specific data. This is specified in more detail below.
Patients (subject of report)
We collect personal data about you when you, or a third party, provide us with information about you in relation to an adverse event that affected you or someone else. Where you are reporting the adverse event yourself, please also refer to the Reporters section.
Pharmacovigilance laws require us to take “detailed records” of every adverse event passed to us, which allow the event to be evaluated and collated with other adverse events recorded about that product. The personal data that we may collect about you when you are the subject of an adverse event report is:
Some of this information is considered by law to be “sensitive personal data” about you. This includes any information that tells us about your:
This information is only processed where relevant and necessary to document your reaction properly and for the purpose of meeting our pharmacovigilance requirements. These requirements exist to allow us and competent pharmacovigilance authorities to diagnose, manage and prevent such adverse events from occurring in the future.
We collect information about you when you provide us with information about you in relation to an adverse event you have reported.
Pharmacovigilance laws require us to ensure that adverse events are traceable and available for follow-up. As a result, we must keep sufficient information about reporters to allow us to contact you once we have received the report. The personal data that we may collect about you when you report an adverse event is your:
Where you are also the subject of a report, this information may be combined with the information you provide in relation to your reaction. However, information about patients, relatives or other non-medical reporters is withheld from Teva’s Global PhV Database (see below).
How we use and share your information
As part of meeting our pharmacovigilance obligations, we may use and share your information to:
Personal data collected from you for pharmacovigilance may also be transferred to a third party in the event that one of our products is sold, assigned or transferred, in which case we would require the buyer, assignee or transferee to treat that personal data in accordance with applicable data protection laws.
We share information with national and European authorities in accordance with pharmacovigilance laws. We are unable to control their use of your data.
Global PhV Database
As our pharmacovigilance obligations require us to review patterns across reports received from every country where we market our products, the analysis is performed by an international group of highly-qualified safety physicians. To meet these requirements, information provided as part of an adverse event report is shared within Teva on a worldwide basis through Teva’s Global PhV Database. This database is also the platform through which Teva uploads adverse event reports to the Eudravigilance database. All information about patients described in Patients (subject of report) may be uploaded to this database. Similarly, all Reporter data fields may be included, except where the reporter is not a health professional.
How we store information and your rights
Because patient safety is so important, we retain all the information we gather about you as a result of an adverse event report to ensure that we can properly assess the safety of our products over time.
You may access and correct your information at any time by contacting Teva’s Pharmacovigilance team at email@example.com. For legal reasons we cannot delete information that has been collected as part of an adverse event report, unless it is inaccurate. We may also require you to provide proper identification before we comply with any request to access or correct your data. Your right to such access or correction may be limited by applicable law.
Teva takes measures to secure your personal data from accidental loss and from unauthorised access, use, alteration or disclosure. Data is transferred securely using SSL encryption and stored on secure servers. Additionally, we take further information security measures including access controls, stringent physical security and robust information collection, storage & processing practices.
All pharmacovigilance databases, including the Global PhV Database, are hosted in Israel by Teva. These are administered and supported around the clock by Teva’s dedicated pharmacovigilance IT teams in Israel, Germany and the United States. Teva also engages Accenture Services Private Limited in India for data entry, administration and data cleansing of a limited part of the pharmacovigilance database.
Patient information may also be transferred worldwide as part of our Global PhV Database (see above).
Your data is submitted to Teva and is hosted and stored in databases on servers situated in Israel, which are owned and maintained by Teva Pharmaceutical Industries Ltd., an Israeli limited liability company whose principal place of business is at:
5 Basel Street
PO Box 3190
Petach Tikva 49131